Novan Inc: Rises on reaching 90% enrollment for skin infection treatment study

NVN Liquidation

19/01/2021 15:17

** Biotech co's shares  NOVN.O  rise 15.06% to $1.46
    ** Co says enrollment for its pivotal late-stage study of
SB206, a topical antiviral gel to treat molluscum contagiosum, 
has reached 90% of about 850 subjects targeted for enrollment
 urn:newsml:reuters.com:*:nGNX2W1FHl
    ** Molluscum contagiosum is a common, contagious skin
infection with the greatest incidence in children aged 1 to 14
years
    ** Co targets completion of patient enrollment in Q1 with
topline efficacy results expected in Q2
    ** Co also reports securing new location to serve as
corporate headquarters and support activities, including
research, development and small-scale manufacturing capabilities
    ** NOVN is up ~81% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))